Fig. 3.
Comparison of AUC for a nanosuspension and a micronized API suspension of a BCS II development candidate (Merck compound B) in rhesus monkeys. The nanosuspension resulted in improved exposures compared to the micronized suspension in a wide dose range, although at doses above 200 mg/kg no further gains in exposure were observed